Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mesoblast Limited | ASX:MSB | Australian Stock Exchange | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.125 | 8.31% | 1.63 | 1.65 | 1.68 | 1.6475 | 1.50 | 1.52 | 7,162,740 | 07:50:00 |
From Nov 2021 to Nov 2024
By Chris Wack
Mesoblast Ltd. shares were up 10% to $2.80 after the company said it submitted substantial new information to the U.S. Food and Drug Administration on clinical and potency assay items identified in a Complete Response Letter from FDA.
The company said the CRL was received in September 2020 in response to the Biologics License Application for remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease.
Mesoblast has maintained an active dialog with the FDA since receiving the CRL, and the new information submitted to the Investigational New Drug file for remestemcel-L in the treatment of children with SR-aGVHD, as guided by FDA, represents a major milestone in its complete response to the FDA.
Remestemcel-L has been granted Fast Track Designation and BLA Priority Review from the FDA.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 03, 2022 12:58 ET (16:58 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Mesoblast Chart |
1 Month Mesoblast Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
